Rezolute meets with FDA on failed congenital hyperinsulinism study

March 24, 2026 7:00 AM

Rezolute Inc. (NASDAQ: RZLT) met with the U.S. Food and Drug Administration on March 17 to discuss its sunRIZE Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found